Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 23,332

Document Document Title
WO/2017/131169A1
[Problem] The purpose of the invention is to provide a drug useful in the prophylaxis or treatment of muscle damage. [Solution] The invention relates to a novel pharmaceutical use of an extract from inflamed tissue inoculated with vaccin...  
WO/2017/126645A1
The purpose of the present invention is to provide a composition for inhibiting the migration of endotoxin into blood. According to the present invention, a composition for inhibiting the migration of endotoxin into blood is provided, wh...  
WO/2017/121333A1
Disclosed is a use of a Cistanche tubulosa extract, isoacteoside and/or a pharmaceutically acceptable salt of isoacteoside for the preparation of a drug or a food, wherein the drug or food is used to protect muscles. The drug is especial...  
WO/2017/118968A1
Novel aminoglycosides, represented by Formulae (I), (Ia), (III) and (IIIa), as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical composition...  
WO/2017/119476A1
Provided are: a composition for preventing neurological diseases; use of a material for preventing neurological diseases; and a method for preventing neurological diseases. It has been discovered that a heat-treated product of an animal/...  
WO/2017/113268A1
The present invention relates to a compound for treating amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and an application of the compound. The invention discloses a compound suppressing a toxicity induced by an rG...  
WO/2017/115789A1
Provided are compositions for recovering and/or ameliorating deterioration of physiological functions due to aging. A cell overexpressing GDF6 protein or an miR-17 family member. A composition for treating aging-related symptoms, said co...  
WO/2017/114339A1
Microencapsulation of β-alanine uses β-alanine as a core material and a mixture of a wall material and an additive as a release material. The additive comprises: a fatty acid-based saturated or unsaturated fatty acid glyceride containi...  
WO/2017/108419A1
Neuregulin-1 (NRG1) or a fragment thereof or vitamin B12 for use in maintaining or increasing muscle function and/or mass in an ageing subject, and/or substantially preventing or reducing muscle wasting in an ageing subject.  
WO/2017/111166A1
According to the present invention, a drug for treating an intracellular TDP-43 content-related disease is developed and provided . In the binding of TDP-43 to a specific mt-tRNA, the binding sites of the respective substances are identi...  
WO/2017/109494A1
The invention relates to improvements in drug delivery and more particularly to the use of Cell Penetrating Agents (CPA's) or Cell Penetrating Peptides (CPP's) which have been stabilized by, for example: i) stapling two amino acids to fo...  
WO/2017/110705A1
The present invention addresses the problem of developing a drug capable of regrowing synapses, which have been damaged and lost due to a neurodegenerative disease, to thereby provide a medicinal composition for preventing or treating a ...  
WO/2017/106354A1
Compositions and methods useful in treating spinal muscular atrophy are provided. The compositions comprise a recombinant adeno-associated viral vector containing an AAV capsid, e.g., AAVrh.10 capsid, and nucleic acid sequences encoding ...  
WO/2017/101858A1
Disclosed is a method for preparing an extended release dosage form comprising cyclobenzaprine hydrochloride as a main component. The method comprises the following steps: mixing the main component with excipients such as magnesium stear...  
WO/2017/101887A1
A healthcare pharmaceutical preparation having magnesium supplementation and anti-oxidation effects, and a preparation method for the healthcare pharmaceutical preparation. The healthcare pharmaceutical preparation comprises a main effec...  
WO/2017/104180A1
The present invention addresses the problem of providing a composition for enhancing: knee-joint-function improving effects obtained through resistance training without using a training apparatus; and skeletal-muscle-function reinforceme...  
WO/2017/106304A1
Provided herein are peptide-oligomer-conjugates. Also provided herein are methods of treating a central nervous system disorder, a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising admin...  
WO/2017/103851A1
The present invention relates to compounds of Formula (XI) wherein R1a, R2a, R3a, R4a, R5a, R6a, and Aa are as defined herein, and pharmaceutically acceptable salts thereof. The compounds of the present invention are inhibitors of hemato...  
WO/2017/103347A1
The invention relates to a combination product including, as active substances, at least lysine and fenugreek or a bioequivalent compound thereof in order to stimulate the appetite. The invention also relates to a cosmetic treatment meth...  
WO/2017/098173A3
The invention relates to the field of medicine. More specifically, the invention relates to the use of compounds, on a patient, in order to prevent and/or treat myopathy, typically muscular dystrophy or cardiomyopathy, or a traumatic inj...  
WO/2017/098731A1
Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which is useful as a therapeutic agent and/or prophylactic agent for diseases associated with abnormalities in mitochondrial functions, such...  
WO/2017/097311A1
The present invention relates to Rufinamide(or active derivatives thereof)for use in the treatment of myotonia, such as myotonia congenita, paramyotonia congenita and myotonic dystrophy.The present invention also relates to a combinatori...  
WO/2017/100193A1
The invention relates to methods and agents useful for treating motor neuron diseases (MNDs), in particular, amyotrophic lateral sclerosis (ALS). Methods and agents for treating various physiological and pathological conditions associate...  
WO/2017/098733A1
Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which exhibits an effect of significant inhibition on cell death induced in cells of patients with diseases associated with abnormalities in...  
WO/2017/099237A1
A compound represented by formula (I) and having a property of modulating the activity of an androgen receptor, or a pharmaceutically acceptable salt of the compound. X represents S or O; Z represents (Ra)n-A-(CR13R14)0-1-(CR11R12)0-1-; ...  
WO/2017/098173A2
The invention relates to the field of medicine. More specifically, the invention relates to the use of compounds, on a patient, in order to prevent and/or treat myopathy, typically muscular dystrophy or cardiomyopathy, or a traumatic inj...  
WO/2017/094743A1
An agent for the treatment and/or prevention of conditions associated with hyperglucocorticoidemia, characterized in containing as an active ingredient a compound indicated by formula (I): (where ring A is (II), ring B is a substituted o...  
WO/2017/085190A1
A composition comprising one or more polyphenols, such as oleuropein, rutin, curcumin or quercetin, can treat or prevent sarcopenia, reduce a loss of muscle functionality (e.g. muscle strength, gait speed, etc.), increase muscle function...  
WO/2017/085138A1
A composition comprising whey protein and optionally Vitamin D and calcium can be administered to an individual to decrease fat deposition in muscle; increase muscle density; improve or maintain muscle quality; and/or treat or prevent mu...  
WO/2017/082288A1
A compound represented by any one of formulae (I) to (XXII), or a pharmaceutically acceptable salt thereof.  
WO/2017/081111A1
The present invention provides compounds of formula (I) (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof for use in the treatment, prevention and/or delay of progression of amyotr...  
WO/2017/083776A1
The invention provides for AAV vectors expressing the ANO5 gene and antioxidant therapy as methods of inducing muscle regeneration and a method of treating muscular dystrophy.  
WO/2017/077516A2
The invention relates to compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions, particularly wherein said telomere related diseases and/or telomere related medical conditions are cance...  
WO/2017/079195A1
Provided herein are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, and compositions comprising such compounds that are useful for increasing the amount of NAD+ in cells. Also disclosed are methods of using the d...  
WO/2017/077516A3
The invention relates to compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions, particularly wherein said telomere related diseases and/or telomere related medical conditions are cance...  
WO/2017/072984A1
The present invention addresses the problem of providing a novel therapeutic agent and treatment method for amyotrophic disorders, more specifically, a therapeutic agent and treatment method for neurogenic atrophy disorders such as amyot...  
WO/2017/069270A1
Provided is a novel compound or a pharmaceutically acceptable salt thereof that is useful for treating or preventing, on the basis of the PAM effects of the GABAB receptor, diseases such as autism spectrum disorder, fragile X syndrome, s...  
WO/2017/065077A1
The purpose of the present invention is to provide a safe muscle-enhancing agent capable of effectively increasing or maintaining muscle mass and muscle strength, and suppressing a decrease in muscle mass and muscle strength. Further pro...  
WO/2017/064193A1
The invention relates to the uses of an SGLT-2 inhibitor, for example improving the health of a subject or treating metabolic myopathies.  
WO/2017/061614A1
The present invention relates to: a calpain activation inhibitor, a muscle damage inhibitor, a muscular endurance improver or a muscle fatigue recovery agent containing, as an active ingredient, an ω-methylsulfinylalkyl isothiocyanate o...  
WO/2017/062468A8
Provided herein are compounds I, II or III and compositions useful in increasing PPAR8 activity. The compounds and compositions provided herein are useful for the treatment of PPAR8 related diseases (e.g., muscular diseases, vascular dis...  
WO/2017/059554A1
The present invention relates to a method and use of the AAV-XBP1S/GFP virus in the prevention and treatment of amyotrophic lateral sclerosis, as presented in the in vivo studies in figure 6/9.  
WO/2017/062468A1
Provided herein are compounds and compositions useful in increasing PPAR8 activity. The compounds and compositions provided herein are useful for the treatment of PPAR8 related diseases (e.g., muscular diseases, vascular disease, demyeli...  
WO/2017/060750A1
The invention relates to the use of a composition from a plant extract of Withania somnifera, to treat or limit development of pathologies of the myelin, including multiple sclerosis disease.  
WO/2017/057562A1
The present invention provides a therapeutic agent and/or a prophylactic agent and the like for a peripheral nerve disorder or a spinal injury having zonisamide or an alkali metal salt thereof as an active ingredient.  
WO/2017/054086A1
A method of treating myopathy in a mammal is provided. The method includes administering to the mammal exosomes genetically modified to incorporate a muscle protein useful to treat the myopathy or nucleic acid encoding the protein.  
WO/2017/059309A1
Compositions and methods of treating a subject with an acute traumatic injury are disclosed. The methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a potassium chann...  
WO/2017/050259A1
Provided are prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.  
WO/2017/049411A1
Disclosed herein are methods and compositions for increasing and decreasing the permeability of the blood brain barrier for the treatment of diseases and conditions and to facilitate the delivery of agents to the brain, as well as method...  
WO/2017/047769A1
In the present invention, a compound selected from cyclobakuchiol A, cyclobakuchiol B and derivatives thereof, a pharmacologically acceptable salt thereof or a prodrug thereof, is a low molecular weight compound having an action of selec...  

Matches 101 - 150 out of 23,332